Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,235.18
(
-1.04%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 115460

Thursday, 02/24/2011 4:47:28 PM

Thursday, February 24, 2011 4:47:28 PM

Post# of 257580
Nice profile piece on Biocon’s founder. Generic insulin could work out well for PFE; the FDA regulates insulin as a small-molecule drug rather than a biologic, and hence generic versions of the insulins from NVO, LLY, and SNY would be automatically substitutable for their branded counterparts.

When PFE announced the Biocon deal in Oct 2010 (#msg-55680051), NVO’s quickly stock fell 10% (#msg-55717310).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today